NCT04930679View on ClinicalTrials.gov

Evaluating Safety of Andiabet on Diabetes Mellitus Type II Patients, Phase I CT.

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 24, 2018

Primary Completion Date

February 22, 2019

Study Completion Date

February 22, 2019

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Andiabet

Each hard capsule includes: 200mg Gynostemma Pentaphyllum Leaf, 200mg Largerstroemia Speciosa Leaf, 133mg Anemarrhena Asphodeloides Whole

Trial Locations (1)

Unknown

Centre of Clinical Pharmacology, Hanoi Medical University, Hanoi

All Listed Sponsors
lead

Centre of Clinical Pharmacology, Hanoi Medical University

OTHER

NCT04930679 - Evaluating Safety of Andiabet on Diabetes Mellitus Type II Patients, Phase I CT. | Biotech Hunter | Biotech Hunter